The Blog
Source-aware guides on vendor benchmark methodology, evidence quality, and how to read peptide market signal without overstating certainty.
The Truth About Reptides
A sourced critique of Reptides' pivot from an RUO peptide vendor direction into a peptide information platform, and why transparency around that change matters.
Voltera Sciences Retatrutide Review: First Impressions, Shipping, and Packaging
A disclosed first-person writeup covering Voltera Sciences shipping, packaging, included BAC water, and why the initial order experience stood out.
Peptide Vendor Coupon Codes and Referral Links (2026)
Current PeptideBenchmark affiliate links and coupon codes for peptide vendors including Ameano Peptides, American Peptide Research, Amino Club, Apex Peptides, LA Peptides, Nationwide Peptides, Next Chems, Orbitrex Peptides, Glacier Aminos, Vortex Research, Vital Core Research, TCore Biotech, Swiss Chems, EZ Peptides, Peptide Supply Co, Peptide Partners, Forge Performance Co, Puratek, Mile High Compounds, NextGenPeps, GenPeptide, Evolve Peptides, Peptime, Voltera Sciences, Silverstone Labs Co, IDUN Peptides, Ignite Peptides, Nura Peptide, and Pepvida.
How PeptideBenchmark Classifies Testing Transparency
What we mean by public verification, public docs, provider-authored vendor-domain reports, and gated certificate depth in the PeptideBenchmark trust system.
Retatrutide TRIUMPH-1: Lilly's New Phase 3 Obesity Data Just Raised the Bar Again
On May 21, 2026, Eli Lilly announced TRIUMPH-1 Phase 3 results for retatrutide. The topline showed 28.3% mean weight loss at 80 weeks, plus an unusually large share of participants reaching 30% or greater weight loss.
Eloralintide: Lilly's Amylin Drug Has the Strongest Standalone Phase 2 Weight-Loss Result So Far
Eloralintide is Eli Lilly's once-weekly selective amylin receptor agonist for obesity. Its Phase 2 Lancet data showed up to 20.1% mean weight loss at 48 weeks, putting it at the front of the standalone amylin race.
How to Read a Peptide COA
A peptide COA can be useful, but only if you read it as a batch-specific analytical document instead of a marketing badge.
Petrelintide: Roche and Zealand's Amylin Bet Is About Tolerability, Not Winning the Weight-Loss Arms Race
Petrelintide is Zealand Pharma and Roche's long-acting amylin analog. Its Phase 2 efficacy looked modest next to CagriSema and amycretin, but its placebo-like GI tolerability may be the real strategic story.
What Peptide Testing Can and Cannot Prove
A peptide test report can be useful, but identity, purity, content, sterility, and endotoxin are different questions. Here is how to read that distinction more carefully.
Anamorelin: Approved in Japan, Rejected in Europe, and Never Approved by FDA
Anamorelin is an oral ghrelin receptor agonist and the first drug approved anywhere for cancer cachexia, but only in Japan. Here is why Europe and the U.S. said no.
Hexarelin: The Most Potent GHRP and the One Ipamorelin Was Built to Replace
Hexarelin may have been the most potent GHRP of its generation, but off-target hormone release, rapid desensitization, and a failed development path explain why newer peptides like ipamorelin replaced it.
Amycretin: Novo Nordisk's Next-Generation Obesity Drug in Oral and Subcutaneous Phase 3
Amycretin is Novo Nordisk's unimolecular GLP-1 and amylin receptor agonist, now in Phase 3 for obesity in both oral and subcutaneous forms. Here is what the trial data actually show.
SLU-PP-332: Not a Peptide, Strong Mouse Data, and No Human Trials
SLU-PP-332 is an ERR agonist sold by peptide vendors as an exercise mimetic, but it is a synthetic small molecule, not a peptide, and all efficacy data remain preclinical.
VIP Peptide FDA Status: Category 1, CIRS Use, and a Long Compounding History
VIP peptide, or vasoactive intestinal peptide, has a real clinical literature, a controversial role in the Shoemaker CIRS protocol, and an unusual FDA Category 1 compounding status in 2026.
SHLP2 Peptide: Real Research, Parkinson's Interest, and No Consumer Breakout
SHLP2 peptide is one of the most interesting mitochondrial-derived peptides beyond humanin and MOTS-c. Here is what the research says about its metabolism, Parkinson's disease relevance, and limited vendor-market presence.
Cerebrolysin: Approved in 50+ Countries, Contested in Trials, and Outside the U.S. Compounding Framework
Cerebrolysin is not a single peptide. It is a porcine-brain-derived peptide mixture used in over 50 countries, backed by a large but disputed clinical literature, and awkward to place inside the normal U.S. peptide-compounding framework.
Retatrutide + Cagrilintide: Why This Stack Has Zero Clinical Trials
The mechanistic case for retatrutide plus cagrilintide is easy to understand. The clinical evidence base is zero. Here is why the stack exists, why the trial gap is probably structural, and why pre-mixed blends make verification harder.
Brenipatide Might Be Lilly's Most Overlooked Peptide Story After Retatrutide
Retatrutide gets the hype, but Lilly's investigational peptide brenipatide is being studied across alcohol use disorder, major depressive disorder, bipolar disorder, smoking relapse, opioid use disorder, and more. Here is what the official trial record actually shows.
Semaglutide vs. Tirzepatide vs. Retatrutide: The Weight Loss Numbers in Plain English
Three incretin drugs, three different receptor profiles, and three very different headline weight-loss numbers. Here is the cleanest plain-language comparison of semaglutide, tirzepatide, and retatrutide, plus the nuance people usually skip.
FDA Peptide Shake-Up: What Kennedy's 12-Peptide Announcement Actually Means
Secretary Kennedy says FDA will remove 12 peptides from Category 2 and begin PCAC review in July 2026. Here is what the official FDA notice confirms, what is scheduled later, and what still is not clear.
Why U.S.-Based Peptide Vendors Still Matter
Overseas sourcing can be cheaper, but price is not the only variable. Domestic fulfillment, verifiable testing, and location transparency can still matter.
3 YouTube Channels Worth Following for Peptide Research
A practical starting list for people who want better peptide YouTube than generic hype, including two channels led by doctors and one strong biohacking educator.
InfiniWell Review: Why BPC-Lx Pro Stood Out to Me
A first-person editorial look at InfiniWell, its physician-formulated positioning, and why the oral BPC-Lx Pro spray stands out as a more convenient alternative to gray-market injectable routes.
EZPeptides Review: Shipping, Retatrutide, and Referral Points
A disclosed first-person writeup covering shipping speed, product experience, BAC water convenience, and whether EZ Peptides feels worth the premium.
Beginner's Guide to Peptides: What They Are, How to Read the Market, and What to Avoid
A practical starting point for understanding peptide categories, vendor noise, evidence quality, and the biggest mistakes beginners make.
How the Vendor Benchmark Works
A transparent walkthrough of how PeptideBenchmark combines Finnrick and Peptide Critic into one ranked board.
Finnrick vs. Peptide Critic: What Each Source Adds
The two source systems do different jobs. This guide explains what each one contributes to the benchmark board.
What a High Vendor Score Does Not Prove
Benchmark scores can be directionally useful, but they are not the same thing as first-party verification.